Trial Profile
An open-label, single-treatment, single-period, single dose, clinical phase 1 study to assess the safety and tolerability of Bivalent Human Papillomavirus (Types 16 L1 & 18 L1) Vaccine of M/s Cadila Healthcare Ltd., India in healthy, adult, female, human subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 01 Apr 2019
Price :
$35
*
At a glance
- Drugs Human papillomavirus vaccine (Primary)
- Indications Human papillomavirus infections
- Focus Adverse reactions
- Sponsors Cadila Healthcare
- 08 Jan 2018 Status changed from not yet recruiting to completed.
- 01 Jun 2017 New trial record